Briacell Therapeutics Price To Book vs. EBITDA
| BCTX Stock | USD 0.53 0.03 5.54% |
For Briacell Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Briacell Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Briacell Therapeutics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Briacell Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Briacell Therapeutics Corp over time as well as its relative position and ranking within its peers.
Briacell |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Briacell Therapeutics. If investors know Briacell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Briacell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Return On Assets (1.26) | Return On Equity (2.06) |
The market value of Briacell Therapeutics is measured differently than its book value, which is the value of Briacell that is recorded on the company's balance sheet. Investors also form their own opinion of Briacell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Briacell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Briacell Therapeutics' market value can be influenced by many factors that don't directly affect Briacell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Briacell Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Briacell Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Briacell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Briacell Therapeutics EBITDA vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Briacell Therapeutics's current stock value. Our valuation model uses many indicators to compare Briacell Therapeutics value to that of its competitors to determine the firm's financial worth. Briacell Therapeutics Corp is rated second in price to book category among its peers. It is number one stock in ebitda category among its peers . Briacell Therapeutics reported EBITDA of (4.77 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Briacell Therapeutics' earnings, one of the primary drivers of an investment's value.Briacell EBITDA vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Briacell Therapeutics |
| = | 6.13 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Briacell Therapeutics |
| = | (4.77 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Briacell EBITDA Comparison
Briacell Therapeutics is currently under evaluation in ebitda category among its peers.
Briacell Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Briacell Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Briacell Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Briacell Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Briacell Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -124.8 K | -118.6 K | |
| Operating Income | -32.8 M | -31.2 M | |
| Net Loss | -4.9 M | -5.2 M | |
| Income Tax Expense | 62.9 K | 59.7 K | |
| Income Before Tax | -4.8 M | -5 M | |
| Total Other Income Expense Net | 28 M | 29.4 M | |
| Net Interest Income | 288 K | 302.4 K | |
| Interest Income | 288 K | 186.2 K | |
| Net Loss | -4.9 M | -5.2 M | |
| Net Loss | -24.2 M | -22.9 M | |
| Change To Netincome | 16.9 M | 17.8 M | |
| Net Loss | (1.17) | (1.23) | |
| Income Quality | 4.89 | 5.14 | |
| Net Income Per E B T | 1.15 | 0.70 |
Briacell Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Briacell Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Briacell Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Briacell Therapeutics' important profitability drivers and their relationship over time.
Use Briacell Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Briacell Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Briacell Therapeutics will appreciate offsetting losses from the drop in the long position's value.Briacell Therapeutics Pair Trading
Briacell Therapeutics Corp Pair Trading Analysis
The ability to find closely correlated positions to Briacell Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Briacell Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Briacell Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Briacell Therapeutics Corp to buy it.
The correlation of Briacell Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Briacell Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Briacell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Briacell Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Briacell Therapeutics position
In addition to having Briacell Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Real Estate theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.